Winald Gerritsen, MD, PHD

Prof dr. Winald Gerritsen is medical oncologist with a background in translational research with a special interest in tumorimmunology in prostate cancer and melanoma. He is currently working at the Radboud University Nijmegen Medical Centre initiating new clinical studies in prostate cancer and melanoma. He is global (co)-PI of several studies in prostate cancer. He is an adjunct professor John Hopkins University and was visiting professor at Oxford University Cancer Center in 2013.
Prof. Gerritsen has chaired the Dutch Society of Gene Therapy and became honorary member of the society. He has served as chairman of the commission of clinical research of the Dutch Cancer Society (KWF). He chaired the commission of biotherapy of the National Translational Cancer Research Network, UK and is a member of the Cancer Research UK Immunotherapy Review Committee. He is chairman of the scientific advisory board of Aglaia Biomedical Ventures. He is also member of the Royal Holland Society of Sciences and Humanities.
Following his medical training at the University of Nijmegen, Prof. Gerritsen achieved his PhD in 1989 on bone marrow transplantation at the Medical School of the Erasmus University of Rotterdam. From 1989 till 1991 he worked as a special fellow at Memorial Sloan Kettering Cancer Center in New York, after which he held several positions at respectively the University Hospital Utrecht, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, the VU Medical Center (VUMC) and the Radboud University Nijmegen Medical Centre. He was director of VUmc Cancer Center Amsterdam.